Search

Your search keyword '"BERGOUGNOUX, LOÏC"' showing total 18 results
Start Over Author "BERGOUGNOUX, LOÏC"
18 results on '"BERGOUGNOUX, LOÏC"'

1. Les méthodes adaptatives : quand et comment les utiliser dans les essais cliniques ?

Author

d’Andon, Anne, Bassompierre, François, Béhier, Jean-Michel, Belorgey, Chantal, Bénichou, Jacques, Berdeaux, Gilles, Bergougnoux, Loic, Bilbault, Pascal, Chassany, Olivier, Brentano, Christian Funck, Gersberg, Martha, Labreveux, Claire, Lassale, Catherine, Lebbé, Céleste, Lecocq, Brigitte, Lévy, Vincent, Montestruc, François, Morgan, Caroline, Nachbaur, Gaelle, Palestro, Brigitte, Paoletti, Xavier, Porcher, Raphaël, Raison, Anne, Spiess, Laurent, Strub, Nathalie, Vitzling, Christian, and Vray, Muriel

Published
2011
Full Text
View/download PDF

2. Adaptive Methods: When and How Should They be Used in Clinical Trials?

Author

d’Andon, Anne, Bassompierre, François, Béhier, Jean-Michel, Belorgey, Chantal, Bénichou, Jacques, Berdeaux, Gilles, Bergougnoux, Loic, Bilbault, Pascal, Chassany, Olivier, Brentano, Christian Funck, Gersberg, Martha, Labreveux, Claire, Lassale, Catherine, Lebbé, Céleste, Lecocq, Brigitte, Lévy, Vincent, Montestruc, François, Morgan, Caroline, Nachbaur, Gaelle, Palestro, Brigitte, Paoletti, Xavier, Porcher, Raphaël, Raison, Anne, Spiess, Laurent, Strub, Nathalie, Vitzling, Christian, and Vray, Muriel

Published
2011
Full Text
View/download PDF

3. Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical Need

Author

Armand, Jean-Pierre, Bardou, Marc, Bergougnoux, Loïc, Bouchet, Christine, Cellier, Dominic, Dahmani, Bachir, Diquet, Bertrand, Lecomte, Thierry, Labouret, Nathalie Hoog, Labreveux, Claire, Meyer, François, Paintaud, Gilles, Piedbois, Pascal, Pigeon, Martine, Manesme, Olivier Amédée, Defrance, Rémy, Tonelli, Dominique, Pinachyan, Karen, Tardieu, Sophie, Sahb-Berkovitch, Rima de, Woronoff-Lemsi, Marie-Christine, and Molimard, Mathieu

Published
2010
Full Text
View/download PDF

4. Critères et méthodologie d’évaluation au remboursement des anticancéreux

Author

Armand, Jean-Pierre, Bardou, Marc, Bergougnoux, Loïc, Bouchet, Christine, Cellier, Dominic, Dahmani, Bachir, Diquet, Bertrand, Lecomte, Thierry, Labouret, Nathalie Hoog, Labreveux, Claire, Meyer, François, Paintaud, Gilles, Piedbois, Pascal, Pigeon, Martine, Manesme, Olivier Amédée, Defrance, Rémy, Tonelli, Dominique, Pinachyan, Karen, Tardieu, Sophie, Sahb-Berkovitch, Rima de, Woronoff-Lemsi, Marie-Christine, and Molimard, Mathieu

Published
2010
Full Text
View/download PDF

6. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

Author

Choquet, Sylvain, Leblond, Veronique, Herbrecht, Raoul, Socié, Gérard, Stoppa, Anne-Marie, Vandenberghe, Peter, Fischer, Alain, Morschhauser, Franck, Salles, Gilles, Feremans, Walter, Vilmer, Etienne, Peraldi, Marie-Noelle, Lang, Philippe, Lebranchu, Yvon, Oksenhendler, Eric, Garnier, Jeanne Luce, Lamy, Thierry, Jaccard, Arnaud, Ferrant, Augustin, Offner, Fritz, Hermine, Olivier, Moreau, Anne, Fafi-Kremer, Samira, Morand, Patrice, Chatenoud, Lucienne, Berriot-Varoqueaux, Nathalie, Bergougnoux, Loïc, and Milpied, Noel

Published
2006
Full Text
View/download PDF

8. Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting

Author

Mourah, Samia, primary, Denis, Marc G., additional, Narducci, Fabienne Escande, additional, Solassol, Jérôme, additional, Merlin, Jean-Louis, additional, Sabourin, Jean-Christophe, additional, Scoazec, Jean-Yves, additional, Ouafik, L’Houcine, additional, Emile, Jean-François, additional, Heller, Remy, additional, Souvignet, Claude, additional, Bergougnoux, Loïc, additional, and Merlio, Jean-Philippe, additional

Published
2015
Full Text
View/download PDF

9. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

Author

UCL - MED - Sciences médicales, Choquet, Sylvain, Leblond, Veronique, Herbrecht, Raoul, Socié, Gérard, Stoppa, Anne-Marie, Vandenberghe, Peter, Fischer, Alain, Morschhauser, Franck, Salles, Gilles, Feremans, Walter, Vilmer, Etienne, Peraldi, Marie-Noelle, Lang, Philippe, Lebranchu, Yvon, Oksenhendler, Eric, Garnier, Jeanne Luce, Lamy, Thierry, Jaccard, Arnaud, Ferrant, Augustin, Offner, Fritz, Hermine, Olivier, Moreau, Anne, Fafi-Kremer, Samira, Morand, Patrice, Chatenoud, Lucienne, Berriot-Varoqueaux, Nathalie, Bergougnoux, Loïc, Milpied, Noel, UCL - MED - Sciences médicales, Choquet, Sylvain, Leblond, Veronique, Herbrecht, Raoul, Socié, Gérard, Stoppa, Anne-Marie, Vandenberghe, Peter, Fischer, Alain, Morschhauser, Franck, Salles, Gilles, Feremans, Walter, Vilmer, Etienne, Peraldi, Marie-Noelle, Lang, Philippe, Lebranchu, Yvon, Oksenhendler, Eric, Garnier, Jeanne Luce, Lamy, Thierry, Jaccard, Arnaud, Ferrant, Augustin, Offner, Fritz, Hermine, Olivier, Moreau, Anne, Fafi-Kremer, Samira, Morand, Patrice, Chatenoud, Lucienne, Berriot-Varoqueaux, Nathalie, Bergougnoux, Loïc, and Milpied, Noel

Abstract

B-cell posttransplantation lymphoproliferative disorder (B-PTLD) is a rare but severe complication of transplantation, with no consensus on best treatment practice. This prospective trial, the first to test a treatment for PTLD, was designed to evaluate the efficacy and safety of rituximab in patients with B-PTLD after solid organ transplantation (SOT). Forty-six patients were included and 43 patients were analyzed. Patients were eligible if they had untreated B-PTLD that was not responding to tapering of immunosuppression. Treatment consisted of 4 weekly injections of rituximab at 375 mg/m2. At day (d) 80, 37 (86%) patients were alive, and the response rate was 44.2%, including 12 complete response/unconfirmed complete response (CR/CRu). The only factor predictive of a response at d80 was a normal lactate dehydrogenase level (P = .007, odds ratio [OR] = 6.9). At d360, responses were maintained in 68% of patients, and 56% of patients were alive. The overall survival rate at 1 year was 67%. We conclude that rituximab is effective and safe in PTLD, with stable responses at 1 year. The response rate and overall survival might be improved by combining rituximab with other treatments.

Published
2006

10. Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

Author

Extra, Jean-Marc, primary, Antoine, Eric C., additional, Vincent-Salomon, Anne, additional, Delozier, Thierry, additional, Kerbrat, Pierre, additional, Bethune-Volters, Anne, additional, Guastalla, Jean-Paul, additional, Spielmann, Marc, additional, Mauriac, Louis, additional, Misset, Jean-Louis, additional, Serin, Daniel, additional, Campone, Mario, additional, Hebert, Christophe, additional, Remblier, Céline, additional, Bergougnoux, Loïc, additional, Campana, Frank, additional, and Namer, Moïse, additional

Published
2010
Full Text
View/download PDF

11. Critères et méthodologie d’évaluation au remboursement des anticancéreux

Author

Sahb-Berkovitch, Rima de, primary, Woronoff-Lemsi, Marie-Christine, additional, Molimard, Mathieu, additional, Armand, Jean-Pierre, additional, Bardou, Marc, additional, Bergougnoux, Loïc, additional, Bouchet, Christine, additional, Cellier, Dominic, additional, Dahmani, Bachir, additional, Diquet, Bertrand, additional, Lecomte, Thierry, additional, Labouret, Nathalie Hoog, additional, Labreveux, Claire, additional, Meyer, François, additional, Paintaud, Gilles, additional, Piedbois, Pascal, additional, Pigeon, Martine, additional, Manesme, Olivier Amédée, additional, Defrance, Rémy, additional, Tonelli, Dominique, additional, Pinachyan, Karen, additional, and Tardieu, Sophie, additional

Published
2010
Full Text
View/download PDF

12. Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical Need

Author

Sahb-Berkovitch, Rima de, primary, Woronoff-Lemsi, Marie-Christine, additional, Molimard, Mathieu, additional, Armand, Jean-Pierre, additional, Bardou, Marc, additional, Bergougnoux, Loïc, additional, Bouchet, Christine, additional, Cellier, Dominic, additional, Dahmani, Bachir, additional, Diquet, Bertrand, additional, Lecomte, Thierry, additional, Labouret, Nathalie Hoog, additional, Labreveux, Claire, additional, Meyer, François, additional, Paintaud, Gilles, additional, Piedbois, Pascal, additional, Pigeon, Martine, additional, Manesme, Olivier Amédée, additional, Defrance, Rémy, additional, Tonelli, Dominique, additional, Pinachyan, Karen, additional, and Tardieu, Sophie, additional

Published
2010
Full Text
View/download PDF

13. Epoetin β Once-Weekly Therapy in Anemic Patients with Solid Tumors and Non-Myeloid Hematological Malignancies Receiving Chemotherapy

Author

Spaëth, Dominique, primary, Desablens, Bernard, additional, Rodon, Philippe, additional, Mennecier, Bertrand, additional, Oudard, Stéphane, additional, Moullet, Isabelle, additional, Ghomari, Kamel, additional, Bergougnoux, Loïc, additional, Bleuzen, Pascal, additional, Jenabian, Arash, additional, and Ifrah, Norbert, additional

Published
2008
Full Text
View/download PDF

16. Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma : 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).

Author

Morschhauser, Franck, Recher, Christian, Milpied, Noel, Gressin, Remi, Salles, Gilles, Brice, Pauline, Vey, Norbert, Haioun, Corinne, Colombat, Philippe, Bourhis, Jean-Henri, Rossi, Jean-Francois, Berriot-Varoqueaux, Nathalie, Bergougnoux, Loic, Bosly, Andre, Delsol, Georges, and Attal, Michel

Published
2004
Full Text
View/download PDF

17. Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

Author

Solal-Celigny, Philippe, Salles, Gilles Andre, Brousse, Nicole, Franchi-Rezgui, Patricia, Soubeyran, Pierre, Delwail, Vincent, Deconinck, Eric, Haioun, Corinne, Foussard, Charles, Sebban, Catherine, Tilly, Herve, Milpied, Noel-Jean, Boue, Francois, Karsenti, Jean-Michel, Lederlin, Pierre, Najman, Albert, Thieblemont, Catherine, Morschhauser, Franck, Berriot-Varoqueaux, Nathalie, Bergougnoux, Loic, and Colombat, Philippe

Published
2004
Full Text
View/download PDF

18. Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy.

Author

Spaëth D, Desablens B, Rodon P, Mennecier B, Oudard S, Moullet I, Ghomari K, Bergougnoux L, Bleuzen P, Jenabian A, and Ifrah N

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Anemia etiology, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Female, Hemoglobins analysis, Humans, Male, Middle Aged, Prospective Studies, Recombinant Proteins, Anemia drug therapy, Erythropoietin therapeutic use, Hematinics therapeutic use, Hematologic Neoplasms complications, Hematologic Neoplasms drug therapy, Neoplasms complications, Neoplasms drug therapy
Abstract

Objectives: This study aimed to provide further clinical evidence for the efficacy and safety of epoetin beta once weekly across a wide range of cancer types., Methods: This was a multicenter, open-label, prospective, single-arm study in patients with either a solid tumor or non-myeloid hematological malignancy, receiving or scheduled to receive further chemotherapy. Patients received epoetin beta 30,000 IU subcutaneously once weekly for 16 weeks. The primary efficacy endpoint was the change in hemoglobin (Hb) level according to the patient's baseline Hb level., Results: A total of 691 patients were included in the intent-to-treat population. Epoetin beta effectively increased Hb levels (a mean increase from baseline of 1.1 g/dl by week 4 and 2.2 g/dl by week 12). Hb response was achieved in 60.4% of all patients and 61.2% of those with baseline Hb <11 g/dl. Hb response was similar in patients with solid tumors (60.5%) and non-myeloid hematological malignancies (60.2%). Type of chemotherapy and baseline platelet count were independent predictive factors for response. Epoetin beta treatment was well tolerated., Conclusions: Epoetin beta 30,000 IU once weekly effectively increases Hb levels, is well tolerated and has similar efficacy in anemic patients with solid tumors or non-myeloid hematological malignancies., (Copyright 2008 S. Karger AG, Basel.)

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results